Search clinical trials for: platinum sensitive peritoneal cancer

Total 88377 results

Benaroya Research Institute
GlaxoSmithKline; Genentech, Inc.

Completed

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University College, London
AstraZeneca; Cancer Research UK

Completed

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (SaPPrOC)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United Kingdom
Duke University
Aventis Pharmaceuticals

Completed

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

United States
The Catholic University of Korea
Korean Cancer Study Group

Completed

Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
CASI Pharmaceuticals, Inc.

Completed

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Ovarian Cancer | Peritoneal Cancer | Fallopian Cancer

United States, Canada
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Taiho Oncology, Inc.
Taiho Pharmaceutical Co., Ltd.

Terminated

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Small Cell Lung Cancer (SCLC)

Japan, Italy, Germany
University of Southern California
Eli Lilly and Company; Aventis Pharmaceuticals

Completed

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

Peritoneal Neoplasms | Ovarian Carcinoma

United States
New Mexico Cancer Care Alliance
Celgene Corporation

Terminated

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Nordic Society of Gynaecological Oncology - Clinical...

Completed

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Ovarian Epithelial Cancer Recurrent

Denmark, Finland, Norway
Emory University
Genentech, Inc.

Withdrawn

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Fallopian Tube Neoplasms | Ovarian Cancer | Primary Peritoneal
Medical Research Council

Completed

Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
M.D. Anderson Cancer Center

Completed

Gleevec Study for Patients With Ovarian Cancer

Ovarian Cancer

United States
WiSP Wissenschaftlicher Service Pharma GmbH
ClinAssess GmbH

Unknown

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (PROVE)

Ovarian Cancer

Germany
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Wuhan University

Unknown

A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer

Recurrent Ovarian Cancer

China
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
University Hospital, Bonn

Unknown

Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer (HIPEC ROC I)

Ovarian Cancer

Germany
National Cancer Institute (NCI)

Completed

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
GlaxoSmithKline

Completed

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Ovarian Cancer | Neoplasms, Ovarian

United States, Canada
Facet Biotech
Biogen

Terminated

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer

United States, Canada
AstraZeneca
ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI

Terminated

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Italy, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Catholic University of the Sacred Heart

Completed

IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer (IPHC)

Ovarian Epithelial Cancer Recurrent
Theradex

Unknown

Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
AGO Study Group
Arbeitsgemeinschaft Gynaekologische Onkologie Austria; MITO

Completed

Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer

Ovarian Cancer

Germany, Belgium, Italy, Austria
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
Symphony Evolution, Inc.

Terminated

Study of XL999 in Patients With Previously Treated Ovarian Cancer

Ovarian Cancer

United States
Centre Francois Baclesse
GlaxoSmithKline; Centre d'Etudes et de Recherche pour l'Intensification du...

Terminated

Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer (TOPO-LAPA)

Cancer | Chemotherapy | Relapse | Ovarian

France
Poniard Pharmaceuticals

Completed

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Russian Federation
National Cancer Institute (NCI)

Completed

Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis

Stomach Neoplasms | Peritoneal Neoplasms

United States
National Cancer Institute (NCI)

Completed

SU5416 and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Peritoneal Neoplasm | Fallopian Tube Neoplasm

United States
Eli Lilly and Company

Completed

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Ovarian Neoplasms | Primary Peritoneal Cancer

Spain, Germany, Belgium, United Kingdom
Eli Lilly and Company

Completed

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Genital Neoplasms, Female | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Pelvic Neoplasms

United States
AGO Study Group

Completed

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
AGO Study Group

Terminated

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Anemia | Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Platinum Sensitve Relapse

Germany
Regeneron Pharmaceuticals

Not yet recruiting

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Atish Choudhury, MD
Bayer; Pfizer; National Comprehensive Cancer Network; Sumitomo Pharma America,...

Not yet recruiting

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Prostate Cancer | Advanced Prostate Cancer | Hormone Sensitive Prostate Cancer

United States
Astellas Pharma Korea, Inc.

Not yet recruiting

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Metastatic Hormone-Sensitive Prostate Cancer
New Approaches to Neuroblastoma Therapy Consortium
Nationwide Children's Hospital; United Therapeutics; Children's Neuroblastoma...

Not yet recruiting

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Neuroblastoma

United States
Uppsala University
Sahlgrenska University Hospital, Sweden; University Hospital, Umeå; Uppsala University... and other collaborators

Not yet recruiting

The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer (Lead4Care)

Prostate Cancer

Sweden
Uppsala University Hospital
Norrlands Universitetssjukhus, Umea, Sweden

Recruiting

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test (FOLL-OV)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Sweden
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR)

Not yet recruiting

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes (OPTION-DDR)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers (I-COMET)

Colon Cancer | Peritoneal Carcinoma

France
Shanghai Jiaolian Drug Research and Development...
Shanghai Pharmaceuticals Holding Co., Ltd

Not yet recruiting

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Platinum-resistant Recurrent Ovarian Cancer

China

Search clinical trials for: platinum sensitive peritoneal cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations